Assessing Quality of Life of Patients With Prostate Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed prostate cancer
• •Stratum I:
• •* Clinically localized primary prostate cancer
• •* T1-T3, G1-G3, N0, M0
• •* Plan to undergo a radical prostatectomy OR
• •* Local or locally advanced primary prostate cancer
• •* T1-T4, G1-G3, N0, M0
• •* Plan to undergo radiotherapy with curative intent
• •Stratum II:
• •* Metastatic prostate cancer
• •* T1-T4, G1-G3, N1, M0-M1 OR
• •* T1-T4, G1-G3, N0-1, M1
• •* Plan to receive hormonal treatment
• •* No anti-androgen monotherapy
• •No cerebral metastases
• •PATIENT CHARACTERISTICS:
• •Age:
• •Any age
• •Performance status:
• •Not specified
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •Not specified
• •Hepatic:
• •Not specified
• •Renal:
• •Not specified
• •Other:
• •Mentally fit to complete a questionnaire
• •Literate in the language of the questionnaires
• •No psychological, familial, sociological, or geographical condition that would preclude compliance
• •No other concurrent malignancy except basal cell skin cancer
• •No concurrent participation in other quality of life investigations that would preclude study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •Not specified
• •Endocrine therapy:
• •See Disease Characteristics
• •No prior neoadjuvant hormonal treatment
• •Planned adjuvant hormonal therapy (orchiectomy, luteinizing hormone-releasing hormone analogue, or maximal androgen blockade) is allowed for patients in stratum I
• •Radiotherapy:
• •See Disease Characteristics
• •No interstitial radiotherapy
• •More than 2 years since prior radiotherapy (stratum II)
• •Surgery:
• •See Disease Characteristics
• •More than 2 years since prior prostatectomy (stratum II)
• •Other:
• •No prior treatment for prostate carcinoma